Memorial Sloan Kettering Westchester

West Harrison, NY

(888) 828-2206

Filters

Help Me Find Trials

Sorting 11 by

Accepting patients

Stopping Maintenance Therapy

Stopping Maintenance Therapy in People With Multiple Myeloma in MRD-Negative Remission

Learn more

Maintenance

Accepting patients

NUTRIVENTION-4

A Study of Health-Related Quality of Life in People With Multiple Myeloma Receiving Daratumumab or Lenalidomide

Learn more

Monoclonal Antibody
CD38
Maintenance
Phase 2

Get personalized results in 60 seconds

All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.

Help me find trials

Not yet accepting

Belantamab Mafodotin Combination Therapy

A Phase I/II Study of the Safety, Tolerability and Efficacy of Belantamab Mafodotin (GSK2857916) in Combination With Iberdomide (CC-220)/Dexamethasone Versus Belantamab Mafodotin (GSK2857916)/Dexamethasone in Relapsed Refractory Multiple Myeloma

Learn more

Antibody Drug Conjugate (ADC)
BCMA
Phase 1/2

Accepting patients

Talquetamab Consolidation After BCMA CAR-T

Talquetamab Consolidation After BCMA CART Cell Therapy for Relapsed or Refractory Multiple Myeloma

Learn more

Bispecific Antibody
GPRC5D
Post-CAR T
Phase 2

Accepting patients

MagnetisMM-30

A Phase 1B, Open-Label Study of Elranatamab in Combination with Iberdomide in Participants with Relapsed Refractory Multiple Myeloma

Learn more

Bispecific Antibody
BCMA
CD3
Phase 1

Accepting patients

Isatuximab After Allogeneic Stem Cell Transplant

Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation

Learn more

Monoclonal Antibody
CD38
Phase 2

Accepting patients

Iberdomide vs. Observation Post Ide-Cel CAR-T

Randomized Phase 2 Study of Iberdomide Maintenance Therapy Following Idecabtagene Vicleucel CAR-T in Multiple Myeloma Patients

Learn more

CELMoD
Maintenance
Randomization
Phase 2

Accepting patients

CyBorD Plus Daratumumab

A Phase II Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab for Patients With Monoclonal Gammopathy of Renal Significance (MGRS)

Learn more